OCGN — Ocugen, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1372299 ·
Last close
$0.76
Market Cap
$256.75M
52W High
$2.72
52W Low
$0.69
ADV30
7,414,813
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,951,000 — -17,753,000 -3,598,000 108,061,000 24,632,000 125,742,000
Jun 2026 1,488,000 — -16,444,000 -24,877,000 124,206,000 100,051,000 140,762,000
Mar 2026 1,533,000 — -17,839,000 -19,177,000 56,905,000 31,855,000 51,100,000
Dec 2025 -193,000 — -16,995,000 -17,706,000 43,516,000 18,571,000 55,682,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-63,692,000
Investing CF
$-59,836,000
Financing CF
$115,515,000
CapEx
$-211,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.20
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-455,719,000
Inventory
—
Receivables
$536,000
ST Investments
$59,625,000
EBIT TTM
$-55,140,000
Pretax Income TTM
$-65,358,000
Interest Exp TTM
$10,218,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,780,000
EBITDA
$-67,703,000
Free Cash Flow
$-21,493,000
Enterprise Value
$318,163,616
Total Cash
$84,257,000
Total Debt
$88,562,000
Shares Out
339,306,603
Trailing EPS
$-0.20
Book Value
$-0.05
ROE
-660.0%
ROA
-52.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,413,000 -62,916,000 -67,846,000 43,516,000 55,682,000 -12,166,000 -56,964,000
Dec 2024 4,055,000 -54,757,000 -54,054,000 82,442,000 52,810,000 29,632,000 -42,142,000
Dec 2023 6,036,000 -65,531,000 -63,078,000 64,547,000 23,983,000 40,564,000 -62,054,000
Dec 2022 2,488,000 -89,071,000 -86,804,000 108,632,000 34,651,000 73,981,000 -60,079,000

TTM Snapshot

Revenues TTM
$4,580,000
NetIncome TTM
$-81,811,000
OpCashFlow TTM
—
Assets (Latest)
$124,206,000
Forward EPS
$-0.25

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.74 · call volume: 311 · put volume: 52
Expected Move to 2027-04-16: ±$0.44 (59.54%) — implied range $0.30 – $1.18 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALLO Allogene Therapeutics, Inc. $257.08M $0.74 —
IPSC Century Therapeutics, Inc. $248.79M $1.37 —
SABS SAB Biotherapeutics, Inc. $265.76M $2.95 —
PLX Protalix BioTherapeutics, Inc. $242.84M $2.88 —
TRXB TRex Bio, Inc. $274.46M $10.00 —

News headlines (Yahoo Finance, 1h cache)

Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy
2026-11-12 18:14 · Yahoo
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
2026-11-10 12:00 · Yahoo
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
2026-11-05 12:40 · Yahoo
Ocugen Inc (OCGN) Q3 2026 Earnings Call Highlights: Three Gene Therapy Programs Reach Phase 3 ...
2026-11-04 21:11 · Yahoo
Ocugen Q3 Earnings Call Highlights
2026-11-04 19:14 · Yahoo
Ocugen, Inc. Q3 2026 Earnings Call Summary
2026-11-04 18:34 · Yahoo
Ocugen (OCGN) Q3 2026 Earnings Call Transcript
2026-11-04 17:30 · Yahoo
Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates
2026-11-04 12:55 · Yahoo
Ocugen: Q3 Earnings Snapshot
2026-11-04 12:14 · Yahoo
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
2026-11-04 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.